These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 371974)

  • 21. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major.
    Peterson CM; Graziano JH; Grady RW; Jones RL; Vlassara HV; Canale VC; Miller DR; Cerami A
    Br J Haematol; 1976 Aug; 33(4):477-85. PubMed ID: 1009020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The iron status of Italian subjects with beta-thalassemia trait.
    Fargion S; Taddei MT; Cappellini MD; Piperno A; Fiorelli G
    Acta Haematol; 1982; 68(2):109-14. PubMed ID: 6812365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral iron chelators.
    Agarwal MB
    Indian Pediatr; 1995 Aug; 32(8):847-51. PubMed ID: 8635826
    [No Abstract]   [Full Text] [Related]  

  • 25. Computed tomography scanning of the liver to determine efficacy of iron chelation therapy in thalassemia major.
    Olivieri NF; Grisaru D; Daneman A; Martin DJ; Rose V; Freedman MH
    J Pediatr; 1989 Mar; 114(3):427-30. PubMed ID: 2921687
    [No Abstract]   [Full Text] [Related]  

  • 26. Defective vitamin D metabolism in thalassemia major.
    Zaino EC; Yeh JK; Aloia J
    Ann N Y Acad Sci; 1985; 445():127-34. PubMed ID: 3874574
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of 2,3-dihydroxybenzoic acid (2,3-DHB) on the elimination of iron in a patient with beta-thalassemia major].
    Jensen M; Bender Ch
    Monatsschr Kinderheilkd (1902); 1977 May; 125(5):587. PubMed ID: 876248
    [No Abstract]   [Full Text] [Related]  

  • 28. Thalassemia in Britain and Australia.
    Modell B; Matthews R
    Birth Defects Orig Artic Ser; 1976; 12(8):13-29. PubMed ID: 795477
    [No Abstract]   [Full Text] [Related]  

  • 29. The relation between liver iron concentration and liver damage in transfusional iron overload in thalassaemia and the effect of chelation therapy.
    Risdon RA; Flynn DM; Barry M
    Gut; 1973 May; 14(5):421. PubMed ID: 4716515
    [No Abstract]   [Full Text] [Related]  

  • 30. Iron chelation in cell cultures by two conjugates of 2,3-dihydroxybenzoic acid (2,3 -DHB).
    Jacobs A; White GP; Tait GP
    Biochem Biophys Res Commun; 1977 Feb; 74(4):1626-30. PubMed ID: 843384
    [No Abstract]   [Full Text] [Related]  

  • 31. Oral iron chelators for the clinical management of iron overload. Current hopes and problems.
    Piomelli S
    Ann N Y Acad Sci; 1990; 612():311-4. PubMed ID: 2291559
    [No Abstract]   [Full Text] [Related]  

  • 32. Proceedings: 5-year controlled trial of chelating agents in treatment of thalassaemia major.
    Flynn DM
    Arch Dis Child; 1973 Oct; 48(10):829. PubMed ID: 4584225
    [No Abstract]   [Full Text] [Related]  

  • 33. The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran.
    Karimi M; Haghpanah S
    Health Policy; 2015 Feb; 119(2):239-43. PubMed ID: 25564279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteochondrodystrophic lesions in chelated thalassemic patients: an histological analysis.
    de Sanctis V; Stea S; Savarino L; Granchi D; Visentin M; Sprocati M; Govoni R; Pizzoferrato A
    Calcif Tissue Int; 2000 Aug; 67(2):134-40. PubMed ID: 10920218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2,3-DHB ineffective in treatment of iron overload.
    Peterson CM; Grady RW; Jones RL; Cerami A; Graziano JH; Markenson AL; Lavi U; Canale V; Gray GF; Miller DR
    N Engl J Med; 1977 Dec; 297(25):1404. PubMed ID: 337140
    [No Abstract]   [Full Text] [Related]  

  • 36. Skin Disorders in Egyptian Children with β-Thalassemia Major.
    Fahmey SS; Taha G; El-Refaey A; Adly S
    J Trop Pediatr; 2018 Apr; 64(2):104-109. PubMed ID: 28510704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First study on iron complexes in blood and organ samples from thalassaemic and normal laboratory mice using Mössbauer spectroscopy.
    Charitou G; Petousis V; Tsertos C; Parpottas Y; Kleanthous M; Phylactides M; Christou S
    Eur Biophys J; 2018 Mar; 47(2):131-138. PubMed ID: 28695249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of membrane peroxidation in thalassaemic erythrocytes by 2,3-dihydroxybenzoic acid.
    Graziano JH; Miller DR; Grady RW; Cerami A
    Br J Haematol; 1976 Mar; 32(3):351-6. PubMed ID: 1252369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Itoic acid synthesis in Bacillus subtilis.
    Peters WJ; Warren RA
    J Bacteriol; 1968 Feb; 95(2):360-6. PubMed ID: 4966543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The colorimetric determination of iron in biological material with reference to its measurement during chelation therapy.
    Goodwin JF; Murphy B
    Clin Chem; 1966 Feb; 12(2):58-69. PubMed ID: 4952422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.